Some commonly used diagnostic antibodies perform well in applications but cross-react with other unrelated proteins. This cross-reactivity may potentially cause unexpected side effects and generate false diagnostic reports. OriGene is proud to announce the development of High-Density Protein Microarray for antibody specificity testing.
High-Density Protein Microarray
Antibody Specificity Validation Technology
Under current specifications, ~17,000 samples were spotted in duplicates on a single nitrocellulose slide. These include 17,000 different overexpression lysates and 708 positive and negative control samples. Serial diluted mouse, human and rabbit IgG mixture as positive controls were spotted on three subarrays highlighted in redboxes. Subarrays highlighted in yellow boxes contain serial diluted HEK293T cell lysates as negative controls. All the subarrays contain standard positive and negative controls as shown in the figure.
Using this microarray spotted with 17,000 different over-expressed proteins, we have validated the specificity of existing HER2 and ERCC1 diagnostic antibody (View publication on the validation of ERCC1 antibodies). This protein microarray technology has also been applied to identify UltraMAB®, the ultra specific antibodies for cancer biomarkers and other important diagnostic targets. Major applications of validation for UltraMAB® include.
- Mono-specificity test
- WB with cell lines and tissue lysates
- IHC staining with over 25 types of normal and cancer human tissues